The stock of Kite Pharma Inc (NASDAQ:KITE) is a huge mover today! About 380,396 shares traded hands. Kite Pharma Inc (NASDAQ:KITE) has risen 0.80% since April 14, 2016 and is uptrending. It has underperformed by 3.89% the S&P500.
The move comes after 8 months positive chart setup for the $2.48 billion company. It was reported on Nov, 16 by Barchart.com. We have $63.30 PT which if reached, will make NASDAQ:KITE worth $570.40 million more.
Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage
Out of 9 analysts covering Kite Pharma (NASDAQ:KITE), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Kite Pharma has been the topic of 22 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Buy” rating given on Thursday, February 25 by Citigroup. The rating was maintained by FBR Capital with “Mkt Perform” on Tuesday, December 8. FBR Capital maintained the stock with “Mkt Perform” rating in Friday, November 13 report. The stock has “Buy” rating given by Mizuho on Tuesday, May 10. As per Tuesday, August 9, the company rating was maintained by Barclays Capital. The firm has “Buy” rating given on Friday, November 13 by Stifel Nicolaus. The rating was upgraded by Vetr to “Buy” on Tuesday, August 4. The firm has “Buy” rating given on Friday, August 14 by Canaccord Genuity. Suntrust Robinson initiated the stock with “Buy” rating in Friday, January 29 report. FBR Capital upgraded the shares of KITE in a report on Tuesday, January 19 to “Outperform” rating.
According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”
Insitutional Activity: The institutional sentiment increased to 1.57 in 2016 Q2. Its up 0.38, from 1.19 in 2016Q1. The ratio increased, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.
State Board Of Administration Of Florida Retirement System has 20,883 shares for 0% of their US portfolio. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Rice Hall James & Ltd Liability Corporation accumulated 0.12% or 41,001 shares. Moreover, Blackrock Ltd Company has 0% invested in Kite Pharma Inc (NASDAQ:KITE) for 46,323 shares. Mutual Of America Cap Management Ltd Liability Corporation has 16,236 shares for 0.02% of their US portfolio. Allianz Asset Mgmt Ag holds 70,481 shares or 0% of its portfolio. Moreover, D E Shaw & has 0% invested in Kite Pharma Inc (NASDAQ:KITE) for 20,621 shares. Rock Springs Management Ltd Partnership holds 80,000 shares or 0.3% of its portfolio. Northern Tru Corporation owns 445,538 shares or 0.01% of their US portfolio. Federated Inc Pa accumulated 12,000 shares or 0% of the stock. Palisade Cap Management Ltd Liability Nj last reported 0.02% of its portfolio in the stock. Huntington Bankshares, a Ohio-based fund reported 332 shares. Metropolitan Life Insurance New York accumulated 0.01% or 28,447 shares. Mariner Invest Grp Limited Company has 9,300 shares for 0.16% of their US portfolio. Rtw Ltd Liability Company last reported 4.88% of its portfolio in the stock.
Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 11 selling transactions for $3.51 million net activity. $509,350 worth of Kite Pharma Inc (NASDAQ:KITE) was sold by BUTITTA CYNTHIA M. $75,270 worth of Kite Pharma Inc (NASDAQ:KITE) was sold by Wiezorek Jeffrey on Thursday, November 10. $812,581 worth of Kite Pharma Inc (NASDAQ:KITE) shares were sold by DOUMANI ROY.
More recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Seekingalpha.com which released: “Kite Pharma: So Much Promise, So Many Questions” on November 07, 2016. Also Forbes.com published the news titled: “Kite Pharma Enters Oversold Territory (KITE)” on October 19, 2016. Finance.Yahoo.com‘s news article titled: “Kite Pharma reports 3Q loss” with publication date: November 09, 2016 was also an interesting one.
KITE Company Profile
Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Firm offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Firm is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.